Clinical Trial Update: A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating darifenacin for increasing warning time in patients with overactive bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Darifenacin (darifenacin)

Snippet

Sponsor: Novartis | Conditions: Overactive Bladder Syndrome | Phase 3 | Status: COMPLETED